BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Reimbursement Expense — Cost of Sales by Year
Reimbursement Expense — Cost of Sales ($M) ($M)
BeOne Medicines Reimbursement Expense — Cost of Sales: -$36M in FY2025, down 3.0% from a year earlier.
Latest, FY2025
-36
Period ended Dec 31, 2025
Change on a year earlier
-3.0%
-37.1 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Collaborative Arrangements Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Reimbursement Expense — Cost of Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -36 | -3.0% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | -37.1 | +341.7% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | -8.40 | +42.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | -5.90 | +210.5% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | -1.90 | -258.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 1.20 | – | Form 10-K (filed 2023-02-27) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Reimbursement Expense — Cost of Sales ($M), annual FY2020–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/reimb-cogs
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.